Thus, there is merit in expanding combinatorial strategies that take advantage of co-administering GLP-1 RAs with anti-inflammatory or neurotrophic agents, and even with conventional PD treatment like levodopa, to mitigate side effects like dyskinesia (Table 3) [56]. The gene discussed is GLP1R; the disease is Parkinson disease.